Neurosense Therapeutics Ltd. (NRSN) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
NeuroSense Therapeutics Ltd. has successfully completed the 18-month dosing phase of its PARADIGM Phase 2b ALS clinical trial, with top-line clinical results expected in early December 2024. Investors and market watchers will be keenly anticipating these results, which could significantly impact the company’s future prospects and stock performance.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
